# An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

> **NCT05299658** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Clene Nanomedicine** · enrollment: 40 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** CNMAu8

## Key facts

- **NCT ID:** NCT05299658
- **Lead sponsor:** Clene Nanomedicine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-13
- **Primary completion:** 2026-06
- **Final completion:** 2026-08
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05299658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05299658, "An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05299658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*